New review reveals how non-genomic estrogen signaling undermines treatment response and fuels tumor progression Hormone receptor–positive breast ...

Sermorelin, a synthetic analog of growth hormone–releasing hormone (GHRH 1–29), has long attracted scientific interest due to ...

Stefan Bornstein, MD, PhD, professor, made it clear during a press conference at the 67th Congress of the German Society of Endocrinology (DGE) that there is more than one interaction between them.

In some cases, HR-positive/HER2-negative breast cancers may over time become resistant to endocrine therapy. This can occur through mutations in the estrogen receptor ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Reviewed by Felix Gussone, MD. Key Takeaways: Hormones control essential processes like growth, metabolism, mood, and ...

The exceptional immune tolerance of the liver is, in part, mediated by entero-pancreatic endocrine factors that enter the portal vein at elevated levels. These endocrine factors signal via cAMP, ...

An analysis of 12-year results from the C9741 breast cancer trial confirmed the benefit of dose-dense versus conventional chemotherapy for patients with node-positive disease, but also showed ...